The new GLP-1 pills, and why most of them aren't peptides

GLP-1 is the molecule that made peptides a dinner-table topic. The drugs built on it, semaglutide and the rest, are injectable for a simple reason: a peptide is a short chain of amino acids, and the gut is very good at taking apart amino acid chains. Swallow one and your digestion treats it like food. So the needle was never a marketing choice. It was chemistry.

That is the backdrop for what landed at the American Diabetes Association's annual meeting in New Orleans this June. Several oral GLP-1 candidates reported phase 2 results within days of each other, and the more interesting story isn't the weight numbers. It's that most of these pills are no longer peptides at all.

What was reported

The headline data came from elecoglipron, an oral GLP-1 receptor agonist from AstraZeneca, with two phase 2 trials published in The Lancet and presented at the meeting. In the obesity trial, called VISTA, and a companion diabetes trial called SOLSTICE in 406 adults, the once-daily pill was associated with roughly 10.5% weight loss in the pooled phase 2 results, and about 72% of people on the 75 mg dose reached at least a 5% reduction by week 26, against roughly 20% on placebo. The company is moving it into a large phase 3 program.

It wasn't alone. Aleniglipron, another oral candidate, reported up to about 12% weight loss over 36 weeks in a 230-person phase 2 trial in Nature Medicine. Orforglipron, further along, became the first oral non-peptide GLP-1 drug to finish a phase 3 program. Three different drugs, the same shape of result, the same week.

The part worth noticing

Each of those is a small molecule, not a peptide. That distinction is the whole point. A small molecule is compact and stable enough to survive digestion, which is why these can be taken with or without food and don't need the absorption tricks that oral peptide formulations rely on. They are also far simpler to manufacture at scale, since you're running chemistry rather than growing the molecule in cells.

So the category that taught the public the word "peptide" is, at its frontier, quietly leaving the peptide behind. The biology being targeted is identical, the same GLP-1 receptor, the same hunger and glucose signaling. What's changing is the key cut to fit it. That's a useful reminder that "peptide" describes a chemical structure, not a mechanism or a benefit. Two drugs can do similar things to the same receptor and only one of them is a peptide.

How to read it

A few cautions keep this in proportion. These are phase 2 results, which means they're promising enough to justify the much larger and longer phase 3 trials, not conclusions. Phase 3 is where weaker effects and rarer problems tend to surface. The gastrointestinal side effects that have followed this whole drug class showed up here too, generally mild to moderate and easing over time, but present.

The weight figures also describe averages across trial populations, not a forecast for any one person, and they sit on top of the diet and medical supervision built into a trial. A number from a study isn't a number you can expect off the shelf.

What this moment actually marks is maturation. A drug class that started as an injection is being reworked into something you can swallow and store at room temperature, and the engineering is changing the molecule itself to get there. That's the interesting result, more than any single percentage: the field is optimizing for how a drug fits into a life, not only for what it does in a vein. Worth watching. Not yet worth concluding.

---

This post is educational and general in nature. It is not medical advice. For guidance about your own health, talk to a qualified clinician.